While undertaking a PhD in cardiovascular medicine at the University of Oxford, sonographer Ross Upton saw the potential of AI for tackling the pain points of traditional echocardiography. 

Echocardiography is the bedrock of heart failure detection, but is subjective, time-consuming, and requires a highly specialized and increasingly rare skillset. As such, diagnosis is often missed or indeterminate, resulting in avoidable invasive procedures and adverse outcomes, including preventable deaths.  

Working with Professor Paul Leeson, Ross designed an algorithm to bypass these limitations, and EchoGo was born.

Unlike traditional systems which automate parameters, EchoGo goes one step further and can identify disease using a Single View Analysis of an echocardiogram, learning to automate a diagnosis using an exclusive partnership and access to Mayo Clinic's database of known-patient outcomes. They officially founded Ultromics in 2017, when the organization was spun-out of the University of Oxford. 

Six years later, we are the leader in AI-driven echocardiography solutions, and on our way to achieving our mission of improving outcomes and guiding timely, efficacious management. With more than twenty published studies, three FDA clearances, two CE marks, two awarded breakthrough designations, two reimbursement codes for billing EchoGo,  and the support of world-renowned partners like Mayo Clinic, FNIH, ASE, Northwestern, and the NHS.